Bukaeva I A, Raĭkhlin N T, Probatova N A, Smirnova E A, Tupitsyn N N, Sholokhova E N, Gossrau R
Institute of Anatomy, Free University, Berlin, Germany.
Arkh Patol. 1997 Jul-Aug;59(4):31-8.
26 cases of lymphoproliferative diseases were studied: 8 cases of reactive follicular hyperplasia (RFH), 11 cases of non-Hodgkin's malignant lymphomas (NML), 7 cases of lymphogranulomatosis (LGM). Only gamma-glutamyl transpeptidase (GGT) was found in lymphoid cells of B- and T-dependent areas of lymph nodes with reactive changes as well as in tumor cells of NML and LGM. GGT activity was more pronounced in NML of high-grade malignancy (centroblast and immunoblast) as compared to lymphomas of lower grade of malignancy (lymphocytic, centroblast-centrocytic and in Lennert lymphoma). GGT activity in cells of Hodgkin and Berezovsky-Sterberg in some cases of LGM was high, in others low. Significant differences in GGT activity between RFH and follicular centroblast-centrocytic lymphoma were not found. Activity of aminopeptidase M was observed in histiocytes, fibroblasts, vessels and areas of connective tissue growth. Aminopeptidase A activity was observed in vessels only. Activity of dipeptidyl(amino)peptidase IV was observed in some lymphoid cells in RFH, NML and LGM. Thus, GGT activity may be considered as a differential-diagnostic marker in separating NML of high and low degree of malignancy and this may presume a different sensitivity to the therapy.
对26例淋巴增生性疾病进行了研究:8例反应性滤泡增生(RFH),11例非霍奇金恶性淋巴瘤(NML),7例淋巴肉芽肿病(LGM)。在有反应性改变的淋巴结B细胞和T细胞依赖区的淋巴细胞以及NML和LGM的肿瘤细胞中仅发现γ-谷氨酰转肽酶(GGT)。与低级别恶性淋巴瘤(淋巴细胞性、中心母细胞-中心细胞性和 Lennert 淋巴瘤)相比,GGT活性在高级别恶性NML(中心母细胞和免疫母细胞)中更为明显。在某些LGM病例中,霍奇金细胞和贝雷佐夫斯基-施特恩贝格细胞中的GGT活性高,而在其他病例中则低。未发现RFH与滤泡中心母细胞-中心细胞性淋巴瘤之间GGT活性有显著差异。氨肽酶M活性在组织细胞、成纤维细胞、血管和结缔组织生长区域中观察到。氨肽酶A活性仅在血管中观察到。二肽基(氨基)肽酶IV活性在RFH、NML和LGM的一些淋巴细胞中观察到。因此,GGT活性可被视为区分高级别和低级别恶性NML的鉴别诊断标志物,这可能意味着对治疗有不同的敏感性。